‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia
Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos was unable to improve disease burden in non-obstructive hypertrophic cardiomyopathy.
‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia Read More »
